InsiderDB

Lobbying disclosures · Lobbying report

BMY: third_quarter 2026 lobbying report

Biosimilars reimbursement issues. Medicare/Medicaid payment reform. Implementation of Inflation Reduction Act of 2022. 340B Program. Prescription drug pricing policy. Prescription drug pricing policy. H.R.1492 - Ensuring Pathways to Innovation Cures (EPIC) Act. ORPHAN Cures Act. MINI Act. H.R.4299 - Protecting Patient Access to Cancer and Complex Therapies Act. H.R.7391 - Community Health Center Drug Pricing Protection Act. H.R.5509 - Safe Step Act. Clinical Trial Modernization Act. Essential medicines/Buy American. Issues related to the 340B Drug Pricing Program. International Reference Prici

Follow BMY
Became public
Oct 19, 2026, 11:39 AM EDT
Event / period date
Not stated
Collected
Nov 11, 2026, 8:08 AM EST

Why this is connected

Legal-name match: BRISTOL-MYERS SQUIBB COMPANY is BRISTOL MYERS SQUIBB CO (https://www.sec.gov/Archives/edgar/data/14272/), differing only in punctuation, "the" or suffix spelling (Corp/Corporation).

Reported lobbying amounts

Income: $80,000.00

These are different reporting measures. They are not added together or treated as spending on one particular bill.

Source evidence

Read the source excerpt or record
{"url":"https://lda.gov/api/v1/filings/f4107a17-88f8-4f17-98b8-2f9465201058/","filing_uuid":"f4107a17-88f8-4f17-98b8-2f9465201058","filing_type":"Q3","filing_type_display":"3rd Quarter - Report","filing_year":2026,"filing_period":"third_quarter","filing_period_display":"3rd Quarter (July 1 - Sep 30)","filing_document_url":"https://lda.gov/filings/public/filing/f4107a17-88f8-4f17-98b8-2f9465201058/print/","filing_document_content_type":"text/html","income":"80000.00","expenses":null,"expenses_method":null,"expenses_method_display":null,"posted_by_name":"Beth Anne Cole","dt_posted":"2026-10-19T11:39:03-04:00","termination_date":null,"registrant_country":"United States of America","registrant_ppb_country":null,"registrant_address_1":"1201 New York Avenue, NW","registrant_address_2":"8th Floor","registrant_different_address":false,"registrant_city":"Washington","registrant_state":"DC","registrant_zip":"20005","registrant":{"id":401103321,"url":"https://lda.gov/api/v1/registrants/401103321/","house_registrant_id":null,"name":"TODD STRATEGY GROUP","description":"​Government Affairs Consulting Firm.","address_1":"1201 New York Avenue, NW","address_2":"8th Floor","address_3":null,"address_4":null,"city":"Washington","state":"DC","state_display":"District of Columbia","zip":"20005","country":"US","country_display":"United States of America","ppb_country":"US","ppb_country_display":"United States of America","contact_name":"BETH ANNE COLE","contact_telephone":"+1 202-352-7761","dt_updated":"2026-07-30T17:35:40.053965-04:00"},"client":{"id":60290,"url":"https://lda.gov/api/v1/clients/60290/","client_id":60290,"name":"BRISTOL-MYERS SQUIBB COMPANY","general_description":"Biopharmaceutical company.","client_government_entity":null,"client_self_select":false,"state":"DC","state_display":"District of Columbia","country":"US","country_display":"United States of America","ppb_state":"DC","ppb_state_display":"District of Columbia","ppb_country":"US","ppb_country_display":"United States of America","effective_date":"2023-01-01"},"lobbying_activities":[{"general_issue_code":"HCR","general_issue_code_display":"Health Issues","description":"Biosimilars reimbursement issues.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":144898,"prefix":null,"prefix_display":null,"first_name":"ERIC","nickname":null,"middle_name":null,"last_name":"BERGREN","suffix":null,"suffix_display":null},"covered_position":"Chief of Staff, Rep. Brett Guthrie; Staff Assistant, Legislative Correspondent, Legislative Assistant, Senior Legislative Assistant, Legislative Director, Chief of Staff - Rep. Ron Lewis; Intern, Rep. Bill Baker","new":false},{"lobbyist":{"id":142860,"prefix":null,"prefix_display":null,"first_name":"KATHERINE","nickname":null,"middle_name":"FLEMING","last_name":"COTTON","suffix":null,"suffix_display":null},"covered_position":"Staff Assistant, Legislative Correspondent, Legislative Assistant - U.S. Representative Brett Guthrie","new":false},{"lobbyist":{"id":69314,"prefix":null,"prefix_display":null,"first_name":"PAUL","nickname":null,"middle_name":null,"last_name":"EDATTEL","suffix":null,"suffix_display":null},"covered_position":"Chief Health Counsel, House Energy & Commerce Committee; Policy Assistant, Office of the Speaker; Professional Staff Member for the Majority at the House Energy & Commerce Committee; Legislative Assistant & Legislative Director, Rep. John Shadegg","new":false},{"lobbyist":{"id":62564,"prefix":null,"prefix_display":null,"first_name":"DANIEL","nickname":null,"middle_name":"M","last_name":"TODD","suffix":null,"suffix_display":null},"covered_position":"Senior Health Counsel, Senate Finance Committee; Special Assistant, Office of Admin. Ct. - Medicare & Medicaid","new":false},{"lobbyist":{"id":152870,"prefix":"mr","prefix_display":"MR.","first_name":"NICOLAS","nickname":null,"middle_name":null,"last_name":"MAGALLANES","suffix":null,"suffix_display":null},"covered_position":"Senior Advisor - House Republican Conference; Policy Advisor/Professional Staff Member - U.S. Representative Lee Terry/Energy and Commerce Committee; Legislative Correspondent/Legislative Aide - U.S. Senator Lamar Alexander","new":false}],"government_entities":[{"id":136,"name":"Centers For Medicare and Medicaid Services (CMS)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"MMM","general_issue_code_display":"Medicare/Medicaid","description":"Medicare/Medicaid payment reform. Implementation of Inflation Reduction Act of 2022. 340B Program. Prescription drug pricing policy.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":144898,"prefix":null,"prefix_display":null,"first_name":"ERIC","nickname":null,"middle_name":null,"last_name":"BERGREN","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":142860,"prefix":null,"prefix_display":null,"first_name":"KATHERINE","nickname":null,"middle_name":"FLEMING","last_name":"COTTON","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":69314,"prefix":null,"prefix_display":null,"first_name":"PAUL","nickname":null,"middle_name":null,"last_name":"EDATTEL","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":62564,"prefix":null,"prefix_display":null,"first_name":"DANIEL","nickname":null,"middle_name":"M","last_name":"TODD","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":152870,"prefix":"mr","prefix_display":"MR.","first_name":"NICOLAS","nickname":null,"middle_name":null,"last_name":"MAGALLANES","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":136,"name":"Centers For Medicare and Medicaid Services (CMS)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"PHA","general_issue_code_display":"Pharmacy","description":"Prescription drug pricing policy. H.R.1492 - Ensuring Pathways to Innovation Cures (EPIC) Act. ORPHAN Cures Act. MINI Act. H.R.4299 - Protecting Patient Access to Cancer and Complex Therapies Act. H.R.7391 - Community Health Center Drug Pricing Protection Act. H.R.5509 - Safe Step Act. Clinical Trial Modernization Act. Essential medicines/Buy American. Issues related to the 340B Drug Pricing Program. International Reference Pricing/Most Favored Nation.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":144898,"prefix":null,"prefix_display":null,"first_name":"ERIC","nickname":null,"middle_name":null,"last_name":"BERGREN","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":142860,"prefix":null,"prefix_display":null,"first_name":"KATHERINE","nickname":null,"middle_name":"FLEMING","last_name":"COTTON","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":69314,"prefix":null,"prefix_display":null,"first_name":"PAUL","nickname":null,"middle_name":null,"last_name":"EDATTEL","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":62564,"prefix":null,"prefix_display":null,"first_name":"DANIEL","nickname":null,"middle_name":"M","last_name":"TODD","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":152870,"prefix":"mr","prefix_display":"MR.","first_name":"NICOLAS","nickname":null,"middle_name":null,"last_name":"MAGALLANES","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":136,"name":"Centers For Medicare and Medicaid Services (CMS)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]}],"conviction_disclosures":[],"foreign_entities":[],"affiliated_organizations":[]}

Congressional trading in BMY

These disclosures provide context. Their presence does not establish a link between a trader and the event.

Original documents control. Public records can be amended, and company connections may require interpretation. Nothing here is investment advice.